ArticleScientific reports2022
In vitro anti-tuberculosis effect of probiotic Lacticaseibacillus rhamnosus PMC203 isolated from vaginal microbiota.
Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 27 citations in OpenAlex.
- Clinical Potential of Novel Microbial Therapeutic LP51 Based on Xerosis-Microbiome Index.Cells · 2024Trial
- Enhancement of Gut Microbial Homeostasis by a Post-NGPNutrients · 2026Article
- Development of Mass Spectrometry-Based SCFA Analysis Methods in Diverse Samples for Microbiome Research.Life (Basel, Switzerland) · 2026Article
- Multidrug-resistant tuberculosis: a comprehensive review of pathogenesis, drug resistance, current treatment and future prospects.Archives of microbiology · 2026Review
- Article
- Gut microbiota and tuberculosis infection: interaction and therapeutic potential.Gut microbes · 2025Review
- Characterization of Gut Microbiota of Honey Bees in Korea.Polish journal of microbiology · 2025Article
- Microbiome therapeutic PMC101 inhibits the translocation of carbapenem-resistant Klebsiella while enhancing eubiosis in antibiotic-induced dysbiosis mice.Medical microbiology and immunology · 2025Article
- Therapeutic potential of Bacillus sonorensis PMC204 membrane vesicles against drug-resistant Mycobacterium tuberculosis.Medical microbiology and immunology · 2025Article
- Insights into Autophagy in Microbiome Therapeutic Approaches for Drug-Resistant Tuberculosis.Cells · 2025Review
- The interplay between probiotics and host autophagy: mechanisms of action and emerging insights.Autophagy · 2025Review
- Using In Vitro Models to Study the Interactions Between Environmental Exposures and Human Microbiota.Microorganisms · 2025Review
- Isolation of New Strains of Lactic Acid Bacteria from the Vaginal Microbiome of Postmenopausal Women and their Probiotic Characteristics.Current microbiology · 2025Article
- Exploring the potential of Lactocaseibacillus rhamnosus PMC203 in inducing autophagy to reduce the burden of Mycobacterium tuberculosis.Medical microbiology and immunology · 2024Article
- A new perspective on gut-lung axis affected through resident microbiome and their implications on immune response in respiratory diseases.Archives of microbiology · 2024Review
- Editorial: Gut-lung axis: tuberculosis and drug resistance.Frontiers in microbiology · 2024Article
- The gut microbiome: A line of defense against tuberculosis development.Frontiers in cellular and infection microbiology · 2023Review
- Host microbiome in tuberculosis: disease, treatment, and immunity perspectives.Frontiers in microbiology · 2023Review
- Impact of the gut-lung axis on tuberculosis susceptibility and progression.Frontiers in microbiology · 2023Review
- The microbiome and the gut-lung axis in tuberculosis: interplay in the course of disease and treatment.Frontiers in microbiology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mycobacterium tuberculosis (M. tb), the etiological agent of tuberculosis (TB), poses a severe challenge for public health and remains the number one cause of death as a single infectious agent. There are 10 million active cases of TB per year with 1.5 million deaths, and 2-3 billion people are estimated to harbor latent M. tb infection. Moreover, the emergence of multi-drug-resistant (MDR), extremely-drug-resistant (XDR), and the recent totally drug-resistant (TDR) M. tb is becoming a global issue that has fueled the need to find new drugs different from existing regimens. In these circumstances, probiotics can be a potential choice, so we focused on developing them as an anti-tuberculosis drug candidate. Here, we report the anti-tubercular activities of Lacticaseibacillus rhamnosus PMC203 isolated from the vaginal microbiota of healthy women. PMC203 exhibited a promising intracellular killing effect against both drug-sensitive and resistant M. tb infected murine macrophage cell line RAW 264.7 without showing any cytotoxicity. Additionally, it also inhibited the growth of M. tb under broth culture medium. PMC203 did not cause weight change or specific clinical symptoms in a 2-week repeated oral administration toxicity test in a guinea pig model. Here, we also found that PMC203 induces autophagy in a dose dependent manner by increasing the signal of well-known autophagy gene markers, suggesting a possible intracellular killing mechanism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.